Promising SEQUOIA-HCM Study Data Justifies Buy Rating for Cytokinetics

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Cytokinetics (CYTK – Research Report), retaining the price target of $120.00.

Joseph Pantginis has given his Buy rating due to a combination of factors related to the promising data from Cytokinetics’ SEQUOIA-HCM study. The study’s sub-analyses presented at the European Society of Cardiology Heart Failure 2025 Congress demonstrated aficamten’s consistent efficacy across different symptom severities and geographic regions in patients with obstructive hypertrophic cardiomyopathy (oHCM).
The findings highlight aficamten’s potential to address the unmet medical needs of patients with mild symptoms who are often not considered for invasive treatments. The data supports the use of aficamten in a broad range of oHCM phenotypes, which could lead to wider adoption and potentially improve patient outcomes, thereby justifying the Buy rating.

Based on the recent corporate insider activity of 167 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CYTK in relation to earlier this year.